Targeted therapy in hormone refractory prostate cancer

被引：0
|
作者：
S. Burbridge
S. Chowdhury
P. G. Harper
机构：
[1] Guy’s Hospital London,Medical Oncology
来源：
Targeted Oncology | 2007年 / 2卷
关键词：
Hormone refractory prostate cancer; Docetaxel; Calcitriol; Angiogenesis; Endothelin-A antagonists; Imatinib; Erlotinib; Sunitinib; Pertuzumab; Matrix metalloproteinase inhibitors; Inhibitors of apoptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Despite recent progress in the treatment of hormone refractory prostate cancer—with a survival advantage seen with docetaxel chemotherapy—there remains a need for further improvements in this important patient group. Novel targeted agents have promise both as single agents, and in combination with chemotherapy. However, further work is needed to identify therapeutic targets and to develop active agents with a view to introducing them into standard clinical practice.
引用
收藏
页码：235 / 240
页数：5
相关论文
共 50 条
  • [31] Chemotherapy for hormone refractory prostate cancer
    Smith, DC
    UROLOGIC CLINICS OF NORTH AMERICA, 1999, 26 (02) : 323 - +
  • [32] Overview: Hormone refractory prostate cancer
    Crawford, ED
    Rosenblum, M
    Ziada, AM
    Lange, PH
    UROLOGY, 1999, 54 (6A) : 1 - 7
  • [33] Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model
    Shanmugam, Rajasubramaniam
    Jayaprakasan, Vetrichelvan
    Gokmen-Polar, Yesim
    Kelich, Stephanie
    Miller, Kathy D.
    Yip-Schneider, Michele
    Cheng, Liang
    Bhat-Nakshatri, Poornima
    Sledge, George W., Jr.
    Nakshatri, Harikrishna
    Zheng, Qi-Huang
    Miller, Michael A.
    DeGrado, Timothy
    Hutchins, Gary D.
    Sweeney, Christopher J.
    PROSTATE, 2006, 66 (14): : 1498 - 1511
  • [34] Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy
    Sciarra, A
    Casale, P
    Colella, D
    Di Chiro, C
    Di Silverio, F
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 1999, 33 (04): : 211 - 216
  • [35] Targeted therapy in prostate cancer
    Corcoran, Niall M.
    Gleave, Martin E.
    HISTOPATHOLOGY, 2012, 60 (01) : 216 - 231
  • [36] Androgen receptor- and E2F-1-targeted thymoquinone therapy for hormone-refractory prostate cancer
    Kaseb, Ahmed O.
    Chinnakannu, Kannagi
    Chen, D.
    Sivanandam, Arun
    Tejwani, Sheela
    Menon, Mani
    Dou, Q. Ping
    Reddy, G. Prem-Veer
    CANCER RESEARCH, 2007, 67 (16) : 7782 - 7788
  • [37] RETROSPECTIVE EVALUATION OF THERAPY WITH KETOCONAZOLE IN HORMONE-REFRACTORY PROSTATE CANCER (HRPC)
    Bonetta, Alberto
    Derelli, Roberto
    ANTICANCER RESEARCH, 2011, 31 (05) : 1942 - 1943
  • [38] PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer
    Meyer, JP
    Gillatt, DA
    PROSTATE CANCER AND PROSTATIC DISEASES, 2002, 5 (01) : 13 - 15
  • [39] NEW AGENTS IN THE THERAPY OF HORMONE-REFRACTORY PATIENTS WITH PROSTATE-CANCER
    KANTOFF, PW
    SEMINARS IN ONCOLOGY, 1995, 22 (01) : 32 - 34
  • [40] When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
    Hamberg, P.
    Verhagen, P. C. M. S.
    de Wit, R.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (09) : 1193 - 1197
12345